Gilead Must Face Claims It Delayed Safer HIV Medications

March 29, 2021, 7:57 PM

Gilead Sciences Inc. must continue defending against a man’s suit alleging its HIV drug Truvada caused kidney and bone damage, following a New Jersey federal court ruling that declined to dismiss his design defect or inadequate warning claims based on federal preemption.

Anthony Gaetano alleged enough facts to rebut a presumption under New Jersey product liability law that a Food and Drug Administration-approved warning is adequate, the U.S. District Court for the District of New Jersey also said March 26.

Gilead faces suits from more than 21,000 plaintiffs who alleged Truvada and several other HIV drugs caused kidney, bone, or...

To read the full article log in. To learn more about a subscription click here.